Efficacy and Safety of Spleen Tyrosine Kinase and VEGFR-2 Dual-Target Kinase Inhibitor (OT202) in Dry Eye: A Randomized, Vehicle-Controlled Phase 2 Trial.

چکیده

To evaluate the efficacy and safety of OT202 (Ocumension Therapeutics [Shanghai] Co, Ltd), a first-in-class, dual-target kinase inhibitor of spleen tyrosine kinase and vascular endothelial growth factor receptor 2, for treating moderate to severe dry eye disease (DED). Multicenter, randomized,…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• خشکی چشم